SCHEMBL6846530

SCHEMBL6846530

CC1(C)CCCC(C(O)c2ccc(Cl)cc2)N1

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 11/20 0.42
SLC6A4 P31645 11/20 0.42
SLC6A3 Q01959 11/20 0.42
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11116777 0.91 SLC6A2 (0.38) SLC6A2SLC6A4SLC6A3
SCHEMBL28660884 0.87 HIF1A (0.39) SLC6A2SLC6A4SLC6A3L3MBTL1
SCHEMBL11112580 0.86 SLC6A3 (0.43) SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL11115369 0.85 SLC6A3 (0.42) SLC6A2SLC6A4SLC6A3
SCHEMBL22443560 0.83 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3
SCHEMBL22453829 0.83 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3
SCHEMBL22452845 0.83 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3
SCHEMBL22443387 0.83 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3
SCHEMBL11112964 0.83 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3
SCHEMBL22443474 0.77 SLC6A2 (0.36) SLC6A2SLC6A4L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2022-05-19 US claimed
EP-3941468-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA Atrogi AB (SE) 2022-01-26 EP claimed
WO-2020188301-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2020-09-24 WO claimed
US-20040146542-A1 Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal FROELICH OLIVIER 2004-07-29 US claimed
US-20020142023-A1 Composition for keeping away vermin NOVARTIS ANIMAL HEALTH US INC. 2002-10-03 US claimed
EP-1087662-B1 COMPOSITION FOR KEEPING AWAY VERMIN NOVARTIS AG (CH) 2002-04-10 EP claimed
US-20010003646-A1 Composition for keeping away vermin FROELICH OLIVIER (FR) 2001-06-14 US claimed
EP-1087662-A1 COMPOSITION FOR KEEPING AWAY VERMIN Novartis AG (CH) 2001-04-04 EP claimed
WO-1999065311-A1 COMPOSITION FOR KEEPING AWAY VERMIN NOVARTIS AG (CH) 1999-12-23 WO claimed
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2022-05-19 US disclosed
EP-3941468-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA Atrogi AB (SE) 2022-01-26 EP disclosed
WO-2020188301-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2020-09-24 WO disclosed
US-20040146542-A1 Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal FROELICH OLIVIER 2004-07-29 US disclosed
US-20020142023-A1 Composition for keeping away vermin NOVARTIS ANIMAL HEALTH US INC. 2002-10-03 US disclosed
EP-1087662-B1 COMPOSITION FOR KEEPING AWAY VERMIN NOVARTIS AG (CH) 2002-04-10 EP disclosed
US-20010003646-A1 Composition for keeping away vermin FROELICH OLIVIER (FR) 2001-06-14 US disclosed
EP-1087662-A1 COMPOSITION FOR KEEPING AWAY VERMIN Novartis AG (CH) 2001-04-04 EP disclosed
WO-1999065311-A1 COMPOSITION FOR KEEPING AWAY VERMIN NOVARTIS AG (CH) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040146542-A1 Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal PLG, PFN1, CUTA SLC6A2 661/4885SLC6A4 1605/4885SLC6A3 1708/4885
US-20010003646-A1 Composition for keeping away vermin VMP1, SERPINC1, VIL1 SLC6A2 895/4885SLC6A4 2177/4885SLC6A3 1305/4885
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA GPR119, SLC5A1, SLC5A2 SLC6A2 1338/4885SLC6A4 1655/4885SLC6A3 806/4885
US-20020142023-A1 Composition for keeping away vermin VMP1, SERPINC1, VIL1 SLC6A2 895/4885SLC6A4 2177/4885SLC6A3 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.